Equities research analysts at JPMorgan Chase & Co. started coverage on shares of Tango Therapeutics (NASDAQ:TNGX – Get Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage set an “overweight” rating and a $46.00 price target on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 55.14% from the stock’s current price.
Several other brokerages have also recently weighed in on TNGX. Jefferies Financial Group upgraded shares of Tango Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the stock from $27.00 to $60.00 in a research note on Thursday, June 25th. Raymond James Financial lowered shares of Tango Therapeutics to a “hold” rating in a research report on Thursday, June 25th. Weiss Ratings cut shares of Tango Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. HC Wainwright increased their price target on shares of Tango Therapeutics from $27.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Finally, B. Riley Financial reiterated a “buy” rating on shares of Tango Therapeutics in a research note on Monday, June 8th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.85.
Check Out Our Latest Stock Analysis on TNGX
Tango Therapeutics Price Performance
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, meeting analysts’ consensus estimates of ($0.32). As a group, analysts expect that Tango Therapeutics will post -1.28 earnings per share for the current year.
Insider Activity
In related news, insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total transaction of $798,930.00. Following the sale, the insider owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. This trade represents a 18.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 81,000 shares of company stock worth $1,989,630 in the last three months. Company insiders own 6.50% of the company’s stock.
Institutional Investors Weigh In On Tango Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the stock. Legal & General Group Plc increased its stake in Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after acquiring an additional 1,640 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Tango Therapeutics by 26.7% in the 4th quarter. Russell Investments Group Ltd. now owns 9,794 shares of the company’s stock worth $87,000 after purchasing an additional 2,065 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Tango Therapeutics by 52.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock worth $58,000 after purchasing an additional 2,243 shares during the period. SG Americas Securities LLC increased its position in shares of Tango Therapeutics by 10.2% during the 1st quarter. SG Americas Securities LLC now owns 24,257 shares of the company’s stock valued at $507,000 after purchasing an additional 2,251 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Tango Therapeutics by 0.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 489,348 shares of the company’s stock valued at $10,237,000 after buying an additional 2,272 shares during the period. Institutional investors own 78.99% of the company’s stock.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.
The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.
Featured Stories
- Five stocks we like better than Tango Therapeutics
- Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet
- Marriott vs. Viking: Why the Better Quarter Doesn’t Mean the Better Decade
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
